Karyopharm Therapeutics Inc. [KPTI] stock Initiated by Piper Sandler analyst, price target now $8

Karyopharm Therapeutics Inc. [NASDAQ: KPTI] stock went on an upward path that rose over 8.79% on Thursday, amounting to a one-week price increase of more than 12.84%. The company report on January 9, 2023 that Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Revenue and Outlines 2023 Objectives.


Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.

Sponsored


– Preliminary Unaudited Full Year 2022 Total Revenue and U.S. XPOVIO® (selinexor) Net Product Revenue Expected to be Approximately $157.7 Million and $120.4 Million, Respectively, Meeting Company’s Guidance –.

– Initiated Pivotal Phase 3 Study Evaluating Selinexor as a Maintenance Therapy in Women with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer; Encouraging Updated Exploratory Subgroup Analysis in Patients with TP53 Wild-Type Endometrial Cancer Continues to Support Study Rationale; Partnership with Foundation Medicine to Develop TP53 Companion Diagnostic –.

Over the last 12 months, KPTI stock dropped by -55.70%. The one-year Karyopharm Therapeutics Inc. stock forecast points to a potential upside of 62.43. The average equity rating for KPTI stock is currently 2.20, trading closer to a bullish pattern in the stock market.

The market cap for the stock reached $250.50 million, with 80.21 million shares outstanding and 74.06 million shares in the current float. Compared to the average trading volume of 2.66M shares, KPTI stock reached a trading volume of 3898889 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Guru’s Opinion on Karyopharm Therapeutics Inc. [KPTI]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for KPTI shares is $8.89 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on KPTI stock is a recommendation set at 2.20. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Piper Sandler have made an estimate for Karyopharm Therapeutics Inc. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on January 19, 2023. While these analysts kept the previous recommendation, RBC Capital Mkts dropped their target price from $7 to $10. The new note on the price target was released on November 04, 2022, representing the official price target for Karyopharm Therapeutics Inc. stock. Previously, the target price had yet another raise to $8, while JP Morgan analysts kept a Neutral rating on KPTI stock. On November 19, 2021, analysts decreased their price target for KPTI shares from 27 to 10.

The Average True Range (ATR) for Karyopharm Therapeutics Inc. is set at 0.36, with the Price to Sales ratio for KPTI stock in the period of the last 12 months amounting to 1.00.

KPTI Stock Performance Analysis:

Karyopharm Therapeutics Inc. [KPTI] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 12.84. With this latest performance, KPTI shares gained by 7.74% in over the last four-week period, additionally sinking by -30.85% over the last 6 months – not to mention a drop of -55.70% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for KPTI stock in for the last two-week period is set at 48.86, with the RSI for the last a single of trading hit 54.29, and the three-weeks RSI is set at 46.06 for Karyopharm Therapeutics Inc. [KPTI]. The present Moving Average for the last 50 days of trading for this stock 4.09, while it was recorded at 3.17 for the last single week of trading, and 5.09 for the last 200 days.

Insight into Karyopharm Therapeutics Inc. Fundamentals:

Operating Margin for any stock indicates how profitable investing would be, and Karyopharm Therapeutics Inc. [KPTI] shares currently have an operating margin of -43.33 and a Gross Margin at +98.00. Karyopharm Therapeutics Inc.’s Net Margin is presently recorded at -59.14.

Karyopharm Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.50 and a Current Ratio set at 3.60.

Karyopharm Therapeutics Inc. [KPTI] Insider Position Details

There are presently around $223 million, or 88.20% of KPTI stock, in the hands of institutional investors. The top three institutional holders of KPTI stocks are: STATE STREET CORP with ownership of 9,010,339, which is approximately -13.044% of the company’s market cap and around 1.40% of the total institutional ownership; BLACKROCK INC., holding 7,912,954 shares of the stock with an approximate value of $26.43 million in KPTI stocks shares; and PALO ALTO INVESTORS LP, currently with $18.78 million in KPTI stock with ownership of nearly 0% of the company’s market capitalization.

Positions in Karyopharm Therapeutics Inc. stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 81 institutional holders increased their position in Karyopharm Therapeutics Inc. [NASDAQ:KPTI] by around 9,319,107 shares. Additionally, 68 investors decreased positions by around 10,150,907 shares, while 22 investors held positions by with 47,422,873 shares. The mentioned changes placed institutional holdings at 66,892,887 shares, according to the latest SEC report filing. KPTI stock had 19 new institutional investments in for a total of 3,548,200 shares, while 24 institutional investors sold positions of 2,898,117 shares during the same period.

LEAVE A REPLY

Please enter your comment!
Please enter your name here